Australia Markets closed

CohBar, Inc. (CWBR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3134-0.0233 (-6.92%)
At close: 04:00PM EST
0.3200 +0.01 (+2.11%)
After hours: 06:53PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.3367
Open0.3400
Bid0.3100 x 800
Ask0.3200 x 800
Day's range0.3079 - 0.3400
52-week range0.3050 - 2.2700
Volume785,462
Avg. volume1,967,187
Market cap26.97M
Beta (5Y monthly)2.63
PE ratio (TTM)N/A
EPS (TTM)-0.2830
Earnings date28 Mar 2022 - 01 Apr 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.13
  • GlobeNewswire

    CohBar to Present at H.C. Wainwright BIOCONNECT Conference

    MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright BIOCONNECT Conference, being held virtually January 10 - 14, 2022. H.C. Wainwright

  • GlobeNewswire

    CohBar Announces Changes to its Board of Directors and R&D Leadership

    Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced changes to its Board of Directors, Scientific Advisory Board (SAB), and R&D leadership. CohBar’s founders Drs. Nir Ba

  • GlobeNewswire

    CohBar’s CEO to Participate in Upcoming BIO Webinar

    MENLO PARK, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced its Chief Executive Officer, Joseph Sarret, MD, JD, will be a participant on the BIO webinar titled “Leveraging JPM Week to Achieve Business Development Goals” on December 2, 2021 at 1:00pm ET. Registration is complimentary at https://bio-org.zoom.us/webinar/regis